Other fields of research are exploring new potential indirect targets, for example p65BTK, an isoform of Bruton’s tyrosine kinase expressed in more than 50% NSCLC samples that acts as a downstream effector of RAF/MEK/ERK pathway in KRAS mutated cell lines; this important oncogene, which up to now has been known to be expressed only in hematopoietic cells, could be targetable by BTK inhibitors like ibrutinib (113). Here, MAP2K7 is linked to non-small cell lung carcinoma.